Table 1.

Summary of CAR T cells in the treatment of B-ALL, B-NHL and CLL.

Disease	Patient populations	Response and relapse	References
B-ALL	53 adults	44/53 (83%) achieved a CR, the median overall survival was 12.9 months.	Park et al.2
	30 paediatric and adults	27/30 (90%) achieved a CR, seven patients who had a complete remission subsequently had a relapse between 6 weeks and 8.5 months after infusion of CAR T cells.	Maude et al.7
	75 paediatric and adults	45/75 (60%) had a CR, the rate of overall survival was 90% at 6 months after infusion and 76% at 12 months after infusion.	Kochenderfer et al.54
	21 paediatric and adults	14/21 (66.7%) achieved a CR.	Lee et al.53
B-NHL	28 adults	6/14 DLBCL patients achieved a CR and 10/14 FL patients achieved a CR.	Schuster et al.60
	7 adults	4/7 (57%) achieved a CR. Three patients are in ongoing CR at 12 months post CAR T cells infusion.	Locke et al.63
	101 adults	CR rate was 54%. With a median follow-up of 15.4 months, with 40% continuing to have a complete response.	Ye et al.66
	15 adults	8/15 (53%) had a CR. Seven patients are in ongoing CR, ranging from 9 to 22 months post CAR T cells infusion.	Schuster et al.60; June and Sadelain61
	7 adults	2/7 achieved a CR, one patient attained a PR, another four patients exhibited SD. Two patients are in ongoing CR at 3 months and 13 months post CAR T cells infusion.	June and Sadelain61
CLL	14 adults	8/14 (58%) achieved an objective response, with 4/14 (29%) achieving a CR. CAR T cells persisted for >5 years in two patients with durable CRs.	Porter et al.59
	3 adults	2CR, 1PR; two of whom experienced long-lasting CR.	Porter et al.59

B-ALL, B-cell acute lymphoblastic leukaemia; B-NHL, B-cell non-Hodgkin lymphoma; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukaemia; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; PR, partial remission; SD, stable disease.